Find a Physician How to Contribute Affiliated Hospitals Clinical Trials




Search Clinical Trials
Protocol DRUG 006-00
Associated
Category
Treatment

Principal
Investigator
Kuzel
Title A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma
Purpose The main purpose of this study is to test how safe and effective the research drug MK-3475 is compared to ipilimumab for advanced melanoma patients.
Overview This is a research study to test MK-3475, a drug that has not been approved by the United States Food and Drug Administration (FDA) for sale in this country, in comparison with ipilimumab (IPI). Patients enrolled in this study will be assigned by chance to get either MK-3475 or IPI. IPI is marketed by the name Yervoyâ„¢. IPI is approved for sale in other countries and by the FDA in the United States, and may be available by prescription for patients with advanced or metastatic melanoma.
Who May
be Eligible
Some of the eligibility criteria include:
  • Participants must have advanced melanoma that cannot be removed by surgery of other local therapy.
  • Participants must be 16 year of age or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Description of Treatment Participants in this study will be assigned by chance to get either MK-3475 or IPI. MK-3475 is given by IV infusion (given through a vein) every 3 weeks. Participants can continue to get MK3475 as long as their disease is not getting worse, they do not need another treatment, and they do not have bad side effects. IPI is also by IV infusion every 3 weeks for a total of 4 doses.


Clinical trial availability changes frequently. Please check this site for new or updated trials that pertain to you.
If you have questions about current or future trials, contact the Cancer Center at 866-LURIE-CC (866-587-4322) or cancertrials@northwestern.edu.
About Us | Job Opportunities | Northwestern University | Maps & Directions | Contact Us
© Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Clinical Cancer Center: 866.LURIE.CC || Chicago Administrative Office: 312.908.5250.
Contact us with questions at: cancer@northwestern.edu
National Comprhensive Cancer Network National Cancer Institute You Tube Facebook